PHAXIAM Therapeutics S.A.
PHXM · NASDAQ
12/31/2023 | 9/30/2023 | 6/30/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $10 | – | $25 | $39 |
| Short-Term Investments | $0 | – | $0 | $0 |
| Receivables | $5 | – | $4 | $3 |
| Inventory | $0 | – | $2 | $1 |
| Other Curr. Assets | $1 | – | $0 | -$0 |
| Total Curr. Assets | $16 | – | $31 | $43 |
| Property Plant & Equip (Net) | $4 | – | $4 | $3 |
| Goodwill | $10 | – | $14 | $0 |
| Intangibles | $0 | – | $17 | $0 |
| Long-Term Investments | $0 | – | $0 | $0 |
| Tax Assets | $0 | – | $0 | $0 |
| Other NC Assets | $22 | – | $0 | $0 |
| Total NC Assets | $35 | – | $35 | $3 |
| Other Assets | $0 | – | $0 | $0 |
| Total Assets | $51 | – | $66 | $46 |
| Liabilities | – | – | – | – |
| Payables | $4 | – | $4 | $2 |
| Short-Term Debt | $4 | – | $1 | $3 |
| Tax Payable | $0 | – | $4 | $0 |
| Deferred Revenue | $0 | – | $0 | $0 |
| Other Curr. Liab. | $8 | – | $8 | $7 |
| Total Curr. Liab. | $15 | – | $17 | $12 |
| LT Debt | $7 | – | $3 | $10 |
| Deferred Rev, NC | $0 | – | $0 | $0 |
| Deferred Tax Liab, NC | $0 | – | $0 | $0 |
| Other NC Liab. | $3 | – | $9 | $0 |
| Total NC Liab. | $10 | – | $12 | $11 |
| Other Liabilities | $0 | – | $0 | $0 |
| Cap. Leases | $0 | – | $0 | $0 |
| Total Liabilities | $26 | – | $29 | $22 |
| Equity | – | – | – | – |
| Pref Stock | $0 | – | $0 | $0 |
| Common Stock | $6 | – | $6 | $3 |
| Retained Earnings | $0 | – | -$12 | -$0 |
| AOCI | -$30 | – | -$7 | -$28 |
| Other Equity | $50 | – | $50 | $49 |
| Total Equity | $26 | – | $37 | $23 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | – | $0 | $0 |
| Total Liab. & Tot. Equity | $51 | – | $66 | $46 |
| Net Debt | $0 | $0 | -$22 | -$25 |